Veterans aged 60 years and older who received a single dose of the respiratory syncytial virus (RSV) prefusion F3 (RSVPreF3) or RSV prefusion F (RSVpreF) vaccine remained protecte ...

Some hospitals are reporting an uptick in respiratory syncytial virus hospitalizations in recent days, though national data — delayed by the federal shutdown — has yet to offer a clear picture.

The effectiveness of a single respiratory syncytial virus (RSV) vaccine dose declined among older adults, potentially suggesting the need for booster shots among this demographic. That is according to ...

A new shot called nirsevimab is supposed to protect kids from the worst effects of RSV, but a huge mismatch between supply and demand has lead to rationing. This article first appeared in The Checkup, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In May, the FDA ...

Credit: Getty Images. The BLA acceptance was supported by data from the randomized, placebo-controlled phase 2b/3 CLEVER trial as well as interim data from the ongoing phase 3 SMART trial. A ...

Vaccination during pregnancy shows about 70% to 80% effectiveness in protecting newborns through antibody transfer. For adults over 60, vaccines demonstrate roughly 75% real-world effectiveness ...

Respiratory syncytial virus vaccinations are now recommended for all adults over age 75 and for high-risk adults between ages 60 and 74, the CDC announced June 26. Previously, vaccination against RSV ...

A Prescription Drug User Fee Act target date of June 7, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

GSK (NYSE:GSK) announced Tuesday that the U.S. FDA accepted its marketing application to evaluate a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, for those aged 50–59 ...